JP2015514808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514808A5 JP2015514808A5 JP2015509103A JP2015509103A JP2015514808A5 JP 2015514808 A5 JP2015514808 A5 JP 2015514808A5 JP 2015509103 A JP2015509103 A JP 2015509103A JP 2015509103 A JP2015509103 A JP 2015509103A JP 2015514808 A5 JP2015514808 A5 JP 2015514808A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- group
- alkoxy
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005843 halogen group Chemical group 0.000 claims 300
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 95
- 229910052799 carbon Inorganic materials 0.000 claims 81
- 125000004093 cyano group Chemical group *C#N 0.000 claims 77
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 68
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 63
- 229910052739 hydrogen Inorganic materials 0.000 claims 51
- 229910052736 halogen Inorganic materials 0.000 claims 50
- 150000002367 halogens Chemical class 0.000 claims 50
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 45
- 229910052760 oxygen Inorganic materials 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 40
- 125000003545 alkoxy group Chemical group 0.000 claims 39
- 125000000623 heterocyclic group Chemical group 0.000 claims 37
- 229910052757 nitrogen Inorganic materials 0.000 claims 35
- 229910052717 sulfur Inorganic materials 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000005842 heteroatom Chemical group 0.000 claims 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 22
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 22
- 125000004043 oxo group Chemical group O=* 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 14
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 14
- 125000004414 alkyl thio group Chemical group 0.000 claims 13
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 12
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 11
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 11
- 150000001721 carbon Chemical group 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims 11
- 125000004434 sulfur atom Chemical group 0.000 claims 11
- 125000005647 linker group Chemical group 0.000 claims 10
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 7
- -1 C 1 -C 4 alkyl Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 230000009424 thromboembolic effect Effects 0.000 claims 6
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 5
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 229940126629 PAR4 antagonist Drugs 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000003836 peripheral circulation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000009862 primary prevention Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000009863 secondary prevention Effects 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 0 C*C(S1)=C*N2C1=CCC(c([o]c1cc(OC)c3)cc1c3[U]CC1=CCCC(c3cc(C)ccc3)=N1)=C2 Chemical compound C*C(S1)=C*N2C1=CCC(c([o]c1cc(OC)c3)cc1c3[U]CC1=CCCC(c3cc(C)ccc3)=N1)=C2 0.000 description 4
- KPDQLGWPKZUSLX-UHFFFAOYSA-N COc([s]1)n[n]2c1nc(-c1cc(c(OCc3c[s]c(-c4cccc(F)c4)n3)cc(OC)c3)c3[o]1)c2 Chemical compound COc([s]1)n[n]2c1nc(-c1cc(c(OCc3c[s]c(-c4cccc(F)c4)n3)cc(OC)c3)c3[o]1)c2 KPDQLGWPKZUSLX-UHFFFAOYSA-N 0.000 description 1
- UNPWYADZEWBXFU-UHFFFAOYSA-N COc([s]1)n[n]2c1nc(-c1cc(c(OCc3c[s]c(C(CC4)(CCC4(F)F)O)n3)cc(OC)c3)c3[o]1)c2 Chemical compound COc([s]1)n[n]2c1nc(-c1cc(c(OCc3c[s]c(C(CC4)(CCC4(F)F)O)n3)cc(OC)c3)c3[o]1)c2 UNPWYADZEWBXFU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638577P | 2012-04-26 | 2012-04-26 | |
| US61/638,577 | 2012-04-26 | ||
| US201361787680P | 2013-03-15 | 2013-03-15 | |
| US61/787,680 | 2013-03-15 | ||
| PCT/US2013/037956 WO2013163279A1 (en) | 2012-04-26 | 2013-04-24 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514808A JP2015514808A (ja) | 2015-05-21 |
| JP2015514808A5 true JP2015514808A5 (enExample) | 2016-02-04 |
| JP6073464B2 JP6073464B2 (ja) | 2017-02-01 |
Family
ID=48407806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509103A Active JP6073464B2 (ja) | 2012-04-26 | 2013-04-24 | 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体 |
Country Status (36)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700457T1 (it) | 2012-04-26 | 2017-11-15 | Bristol Myers Squibb Co | DERlVATI IMIDAZOTIADIAZOLICI E IMIDAZOPIRAZINICI COME INIBITORI DEL RECETTORE ATTIVATO DA PROTEASI 4 (PAR4) PER IL TRATTAMENTO DELL'AGGREGAZIONE PIASTRINICA |
| EP2855489B1 (en) | 2012-04-26 | 2017-01-04 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| EA201491967A1 (ru) | 2012-04-26 | 2015-03-31 | Бристол-Майерс Сквибб Компани | Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| US9598419B1 (en) | 2014-06-24 | 2017-03-21 | Universite De Montreal | Imidazotriazine and imidazodiazine compounds |
| US9617279B1 (en) | 2014-06-24 | 2017-04-11 | Bristol-Myers Squibb Company | Imidazooxadiazole compounds |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| ES2929208T3 (es) | 2015-02-26 | 2022-11-25 | Univ Montreal | Compuestos de imidazotiadiazol como inhibidores de PAR4 |
| WO2016138199A1 (en) | 2015-02-26 | 2016-09-01 | Bristol-Myers Squibb Company | Benzothiazole and benzothiophne compounds |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| US9789087B2 (en) | 2015-08-03 | 2017-10-17 | Thomas Jefferson University | PAR4 inhibitor therapy for patients with PAR4 polymorphism |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2017066863A1 (en) | 2015-10-19 | 2017-04-27 | Universite De Montreal | Heterocyclic compounds as inhibitors of platelet aggregation |
| US9963466B2 (en) | 2016-03-07 | 2018-05-08 | Vanderbilt University | Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists |
| WO2017184520A1 (en) * | 2016-04-18 | 2017-10-26 | Vanderbilt University | Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists |
| JP7102388B2 (ja) | 2016-07-14 | 2022-07-19 | ブリストル－マイヤーズ スクイブ カンパニー | 単環式ヘテロアリール置換化合物 |
| US10730868B2 (en) | 2016-07-14 | 2020-08-04 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| JP6903732B2 (ja) * | 2016-07-14 | 2021-07-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｐａｒ４阻害剤としての三環式ヘテロアリール置換のキノリンおよびアザキノリン化合物 |
| WO2018013774A1 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| CN113480530A (zh) | 2016-12-26 | 2021-10-08 | 阿里根公司 | 芳香烃受体调节剂 |
| KR20200089718A (ko) | 2017-11-20 | 2020-07-27 | 아리아젠, 인크. | 인돌 화합물 및 이의 용도 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN111094300B (zh) * | 2018-01-31 | 2022-09-16 | 江苏恒瑞医药股份有限公司 | 苯并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| CN110218218B (zh) * | 2018-03-01 | 2022-04-08 | 江苏恒瑞医药股份有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
| CN110272436A (zh) * | 2018-03-14 | 2019-09-24 | 中国药科大学 | 氘代的咪唑并噻二唑衍生物及其医药用途 |
| WO2019218956A1 (zh) * | 2018-05-16 | 2019-11-21 | 深圳信立泰药业股份有限公司 | 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物 |
| CN112074522B (zh) * | 2018-05-16 | 2022-08-26 | 深圳信立泰药业股份有限公司 | 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物 |
| CN110627817B (zh) * | 2018-06-25 | 2022-03-29 | 中国药科大学 | 咪唑并环类par4拮抗剂及其医药用途 |
| KR20210052435A (ko) * | 2018-08-30 | 2021-05-10 | 니혼 메디피직스 가부시키가이샤 | 방사성 이미다조티아디아졸 유도체 화합물 |
| US20230054194A1 (en) | 2018-11-19 | 2023-02-23 | Ariagen, Inc. | Methods of Treating Cancer |
| SG11202106561RA (en) * | 2018-12-21 | 2021-07-29 | Bristol Myers Squibb Co | Crystalline forms of a par4 inhibitor |
| CN111349105B (zh) * | 2018-12-24 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
| CN111362970A (zh) * | 2018-12-25 | 2020-07-03 | 天津药物研究院有限公司 | 苯并呋喃类衍生物及其制备方法和用途 |
| CA3137027A1 (en) | 2019-04-15 | 2020-10-22 | Ariagen, Inc. | Chiral indole compounds and their use |
| EP3782702A1 (en) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compounds and use thereof for the treatment of infectious diseases and cancer |
| CN112079791A (zh) * | 2020-08-21 | 2020-12-15 | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用 |
| CN113150005B (zh) * | 2021-04-09 | 2022-08-30 | 中国药科大学 | 喹喔啉类化合物、制备方法及其在医药上的应用 |
| US12077607B2 (en) | 2021-09-23 | 2024-09-03 | University Of Utah Research Foundation | Functional and therapeutic effects of PAR4 cleavage by cathepsin G |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2823686A1 (de) * | 1978-05-31 | 1979-12-06 | Bayer Ag | Imidazo eckige klammer auf 2.1-b eckige klammer zu eckige klammer auf 1.3.4 eckige klammer zu -thiadiazole |
| DE3020421A1 (de) | 1980-05-29 | 1981-12-10 | Bayer Ag, 5090 Leverkusen | Imidazoazolalkensaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln |
| NO811630L (no) | 1980-05-29 | 1981-11-30 | Bayer Ag | Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel |
| DE3446778A1 (de) * | 1984-12-21 | 1986-07-03 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| US4925849A (en) | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| CA2060138A1 (en) | 1991-01-29 | 1992-07-30 | Youichi Shiokawa | New use of the adenosine antagonist |
| US5342851A (en) * | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| JP4345230B2 (ja) | 1998-03-10 | 2009-10-14 | 小野薬品工業株式会社 | カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤 |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| PT1218383E (pt) | 1999-10-08 | 2009-01-29 | Gruenenthal Gmbh | Derivados bicíclicos de imidazo-5-il-amina |
| DE10019714A1 (de) | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen |
| US6387942B2 (en) | 2000-06-19 | 2002-05-14 | Yung Shin Pharmaceutical Ind. Co. Ltd | Method of treating disorders related to protease-activated receptors-induced cell activation |
| EP1442028A4 (en) | 2001-11-06 | 2009-11-04 | Bristol Myers Squibb Co | SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS |
| CA2364985A1 (en) | 2001-12-14 | 2003-06-14 | John W. Gillard | Imidazo(2,1-b)thiadiazole sulfonamides |
| WO2004063159A1 (ja) | 2003-01-10 | 2004-07-29 | Idemitsu Kosan Co., Ltd. | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| WO2004111060A1 (en) | 2003-06-13 | 2004-12-23 | Aegera Therapeutics Inc. | IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES |
| EP1636242A1 (en) | 2003-06-13 | 2006-03-22 | Aegera Therapeutics Inc. | Acylated imidazo (2,1-b) -1,3,4,-thiadia zole-2-sulfonamides, and uses thereof |
| CN1897939A (zh) | 2003-10-31 | 2007-01-17 | 詹森药业有限公司 | 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物 |
| US20050267182A1 (en) | 2003-11-13 | 2005-12-01 | Ambit Biosciences Corporation | Urea derivatives as FLT-3 modulators |
| EP1713784A1 (en) | 2004-02-12 | 2006-10-25 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| JPWO2006109846A1 (ja) | 2005-04-06 | 2008-11-20 | 武田薬品工業株式会社 | トリアゾール誘導体およびその用途 |
| US20070031328A1 (en) | 2005-06-24 | 2007-02-08 | Kung Hank F | Radiolabeled-pegylation of ligands for use as imaging agents |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| CA2646430A1 (en) | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| AU2007240082A1 (en) | 2006-04-13 | 2007-10-25 | Aegera Therapeutics Inc. | Use of imidazo[2,1-b)]-1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain |
| DE102006054757A1 (de) | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
| PT2155747E (pt) | 2007-05-10 | 2012-12-19 | Ge Healthcare Ltd | Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2 |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| US20120121540A1 (en) | 2007-08-10 | 2012-05-17 | Franz Ulrich Schmitz | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections |
| WO2009027733A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents |
| GB0718735D0 (en) | 2007-09-25 | 2007-11-07 | Prolysis Ltd | Antibacterial agents |
| WO2009079683A1 (en) | 2007-12-21 | 2009-07-02 | The University Of Sydney | Translocator protein ligands |
| TW201002705A (en) | 2008-03-31 | 2010-01-16 | Metabolex Inc | Oxymethylene aryl compounds and uses thereof |
| KR20110042286A (ko) | 2008-07-15 | 2011-04-26 | 사노피-아벤티스 | Ｅｄｇ－１ 수용체 작용제로서의 옥사졸로피리미딘 |
| EP2331530B8 (en) | 2008-09-26 | 2013-12-25 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| WO2010075376A2 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| ES2574253T3 (es) * | 2009-12-18 | 2016-06-16 | Mitsubishi Tanabe Pharma Corporation | Nuevo agente antiplaquetario |
| CN102372701A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 氮杂双环己烷类衍生物、其制备方法及其在医药上的应用 |
| MA34797B1 (fr) | 2010-08-11 | 2014-01-02 | Millennium Pharm Inc | Hétéroaryles et leurs utilisations |
| KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
| EP2855489B1 (en) | 2012-04-26 | 2017-01-04 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| SMT201700457T1 (it) * | 2012-04-26 | 2017-11-15 | Bristol Myers Squibb Co | DERlVATI IMIDAZOTIADIAZOLICI E IMIDAZOPIRAZINICI COME INIBITORI DEL RECETTORE ATTIVATO DA PROTEASI 4 (PAR4) PER IL TRATTAMENTO DELL'AGGREGAZIONE PIASTRINICA |
| EA201491967A1 (ru) | 2012-04-26 | 2015-03-31 | Бристол-Майерс Сквибб Компани | Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов |
| CA2871640A1 (en) | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Par4 agonist peptides |
| MA37439B1 (fr) | 2012-04-27 | 2017-02-28 | Novartis Ag | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). |
| PT2861579T (pt) | 2012-05-15 | 2018-04-27 | Novartis Ag | Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| CN104583233B (zh) | 2012-06-21 | 2018-10-23 | 印第安纳大学研究及科技有限公司 | 表现出gip受体活性的胰高血糖素的类似物 |
| AR092348A1 (es) | 2012-07-11 | 2015-04-15 | Hoffmann La Roche | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc |
| TW201414737A (zh) | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| CA2879460C (en) | 2012-07-18 | 2021-10-19 | Garrett MORASKI | 5,5-heteroaromatic anti-infective compounds |
| TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β－分泌酶抑制劑 |
| NZ705759A (en) | 2012-10-16 | 2019-01-25 | Janssen Sciences Ireland Uc | Rsv antiviral compounds |
| EP2935249B1 (en) | 2012-12-19 | 2018-12-12 | Novartis AG | Autotaxin inhibitors |
| CA2893843C (en) | 2012-12-21 | 2018-09-04 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
-
2013
- 2013-04-24 SM SM20170457T patent/SMT201700457T1/it unknown
- 2013-04-24 MX MX2014012296A patent/MX354175B/es active IP Right Grant
- 2013-04-24 RS RS20170983A patent/RS56395B1/sr unknown
- 2013-04-24 RS RS20191664A patent/RS59882B1/sr unknown
- 2013-04-24 PL PL19192142.8T patent/PL3632919T3/pl unknown
- 2013-04-24 UY UY0001034763A patent/UY34763A/es unknown
- 2013-04-24 PT PT137218574T patent/PT2841437T/pt unknown
- 2013-04-24 EP EP17172927.0A patent/EP3243826B1/en active Active
- 2013-04-24 HR HRP20171453TT patent/HRP20171453T1/hr unknown
- 2013-04-24 CN CN201810251394.6A patent/CN108383858B/zh active Active
- 2013-04-24 NZ NZ631027A patent/NZ631027A/en unknown
- 2013-04-24 HU HUE13721857A patent/HUE034566T2/hu unknown
- 2013-04-24 PT PT171729270T patent/PT3243826T/pt unknown
- 2013-04-24 RS RS20230041A patent/RS63975B1/sr unknown
- 2013-04-24 SG SG11201406757SA patent/SG11201406757SA/en unknown
- 2013-04-24 LT LTEP13721857.4T patent/LT2841437T/lt unknown
- 2013-04-24 SM SM20230004T patent/SMT202300004T1/it unknown
- 2013-04-24 ES ES19192142T patent/ES2935173T3/es active Active
- 2013-04-24 SI SI201331625T patent/SI3243826T1/sl unknown
- 2013-04-24 FI FIEP19192142.8T patent/FI3632919T3/fi active
- 2013-04-24 PL PL13721857T patent/PL2841437T3/pl unknown
- 2013-04-24 SI SI201332026T patent/SI3632919T1/sl unknown
- 2013-04-24 HR HRP20221495TT patent/HRP20221495T1/hr unknown
- 2013-04-24 EP EP19192142.8A patent/EP3632919B1/en active Active
- 2013-04-24 DK DK19192142.8T patent/DK3632919T3/da active
- 2013-04-24 LT LTEP19192142.8T patent/LT3632919T/lt unknown
- 2013-04-24 ES ES13721857.4T patent/ES2640916T3/es active Active
- 2013-04-24 CA CA2871650A patent/CA2871650C/en active Active
- 2013-04-24 KR KR1020147030174A patent/KR102098804B1/ko active Active
- 2013-04-24 PE PE2014001782A patent/PE20142285A1/es active IP Right Grant
- 2013-04-24 ES ES17172927T patent/ES2770026T3/es active Active
- 2013-04-24 DK DK17172927.0T patent/DK3243826T3/da active
- 2013-04-24 SI SI201330734T patent/SI2841437T1/sl unknown
- 2013-04-24 EA EA201491968A patent/EA026724B1/ru not_active IP Right Cessation
- 2013-04-24 PT PT191921428T patent/PT3632919T/pt unknown
- 2013-04-24 US US14/396,771 patent/US9688695B2/en active Active
- 2013-04-24 JP JP2015509103A patent/JP6073464B2/ja active Active
- 2013-04-24 AU AU2013251632A patent/AU2013251632B2/en active Active
- 2013-04-24 EP EP13721857.4A patent/EP2841437B1/en active Active
- 2013-04-24 KR KR1020207031590A patent/KR20200127273A/ko not_active Ceased
- 2013-04-24 PL PL17172927T patent/PL3243826T3/pl unknown
- 2013-04-24 CN CN201380032304.XA patent/CN104583218B/zh active Active
- 2013-04-24 HU HUE19192142A patent/HUE060743T2/hu unknown
- 2013-04-24 DK DK13721857.4T patent/DK2841437T3/en active
- 2013-04-24 HU HUE17172927A patent/HUE048654T2/hu unknown
- 2013-04-24 KR KR1020207009636A patent/KR102176379B1/ko active Active
- 2013-04-24 TW TW102114695A patent/TWI572605B/zh active
- 2013-04-24 BR BR112014026643-3A patent/BR112014026643B1/pt active IP Right Grant
- 2013-04-24 AR ARP130101380A patent/AR090834A1/es active IP Right Grant
- 2013-04-24 WO PCT/US2013/037956 patent/WO2013163279A1/en not_active Ceased
- 2013-04-24 SM SM20200049T patent/SMT202000049T1/it unknown
- 2013-04-24 MY MYPI2014703169A patent/MY175061A/en unknown
-
2014
- 2014-09-29 PH PH12014502173A patent/PH12014502173B1/en unknown
- 2014-10-20 TN TN2014000436A patent/TN2014000436A1/fr unknown
- 2014-10-21 CO CO14232423A patent/CO7160040A2/es unknown
- 2014-10-21 IL IL235246A patent/IL235246B/en active IP Right Grant
- 2014-10-24 ZA ZA2014/07799A patent/ZA201407799B/en unknown
- 2014-10-27 CL CL2014002915A patent/CL2014002915A1/es unknown
-
2017
- 2017-05-12 US US15/593,534 patent/US10047103B2/en active Active
- 2017-09-29 CY CY20171101023T patent/CY1119466T1/el unknown
-
2018
- 2018-06-27 US US16/020,043 patent/US10428077B2/en active Active
-
2019
- 2019-08-13 US US16/538,917 patent/US10822343B2/en active Active
- 2019-12-30 HR HRP20192336TT patent/HRP20192336T1/hr unknown
-
2020
- 2020-01-24 CY CY20201100069T patent/CY1122625T1/el unknown
-
2022
- 2022-09-02 US US17/902,618 patent/US12084452B2/en active Active
-
2024
- 2024-09-06 US US18/826,736 patent/US20250002497A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514806A5 (enExample) | ||
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| JP2015518004A5 (enExample) | ||
| CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2019537570A5 (enExample) | ||
| EA201890888A1 (ru) | Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53 | |
| JP2017533968A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
| JP2014513110A5 (enExample) | ||
| JP2016538313A5 (enExample) | ||
| MX379459B (es) | Inhibidores de bromodominios. | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| JP2016523974A5 (enExample) | ||
| WO2015132799A3 (en) | Heterocyclic compounds | |
| JP2014513139A5 (enExample) | ||
| MX379425B (es) | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia. | |
| JP2013510120A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2019519586A5 (enExample) | ||
| SI2953948T1 (en) | Fluorinated integrin antagonists | |
| JP2017517565A5 (enExample) | ||
| HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака |